{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:44:48Z","timestamp":1792421088706,"version":"4.5.0"},"reference-count":31,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:p>\n                    <jats:bold>\n                      <jats:italic toggle=\"yes\">Background:<\/jats:italic>\n                    <\/jats:bold>\n                    Ceftriaxone is frequently administered empirically for hospitalized patients with acute pyelonephritis (APN) due to prevalent quinolone resistance in our hospital; however, its use is inappropriate for extended-spectrum beta-lactamase (ESBL)-producing\n                    <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                    , an increasing problem.\n                    <jats:bold>\n                      <jats:italic toggle=\"yes\">Methods:<\/jats:italic>\n                    <\/jats:bold>\n                    A retrospective, 1:2 matched cohort study was performed to evaluate the impact of ESBL on APN treated with empirical ceftriaxone. Each patient in ESBL group was matched with two patients in the non-ESBL group, using a 16-point scoring system, which included age, sex, bacteremia, simplified acute physiology score 2, Charlson comorbidity index and APN severity score.\n                    <jats:bold>\n                      <jats:italic toggle=\"yes\">Results:<\/jats:italic>\n                    <\/jats:bold>\n                    From 2009 to 2011, among 1,322 community-onset cases of the\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    bacteriuria with 212 (16%) ESBL producers, 261 patients with APN were treated empirically with ceftriaxone in a secondary care hospital. Among these 261 cases, twenty-six patients in the ESBL group and 52 matched patients in the non-ESBL group (1:2) were included. Mean time to defervescence was 4.6\u00b12.2 days in the ESBL group and 2.6\u00b11.3 days in the non-ESBL group (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    &lt;0.01). Rate of microbiological resolution within 5 days after antibiotic treatment was 77% (17\/22) in the ESBL group and 100% (45\/45) in the non-ESBL group (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    =0.01). The duration of hospitalization was 13.3\u00b18.2 days in the ESBL group and 7.3\u00b13.5 days in the non-ESBL group (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    &lt;0.01). No patient died in either group.\n                    <jats:bold>\n                      <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic>\n                    <\/jats:bold>\n                    Empirical ceftriaxone therapy for APN caused by ESBL-producing\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    is inappropriate, and consequently can delay recovery and result in longer hospitalization.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2013.0075","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T16:42:13Z","timestamp":1376412133000},"page":"39-44","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of Extended-Spectrum Beta-Lactamase on Acute Pyelonephritis Treated with Empirical Ceftriaxone"],"prefix":"10.1177","volume":"20","author":[{"given":"Shinwon","family":"Lee","sequence":"first","affiliation":[{"name":"Daegu Fatima Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Young","family":"Song","sequence":"additional","affiliation":[{"name":"Daegu Fatima Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hyun","family":"Cho","sequence":"additional","affiliation":[{"name":"Kyungpook National University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Tae","family":"Kwon","sequence":"additional","affiliation":[{"name":"Daegu Fatima Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,2]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq152"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05913-11"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11739-009-0250-7","article-title":"Usefulness of simplified acute physiology score II in predicting mortality in patients admitted to an emergency medicine ward","volume":"4","author":"Cosentini R.","year":"2009","unstructured":"Cosentini R., , Folli C., , Cazzaniga M., , Aliberti S., , Piffer F., , Grazioli L., , Milani G., , Pappalettera M., , Arioli M., , Tardini F., et al. 2009. Usefulness of simplified acute physiology score II in predicting mortality in patients admitted to an emergency medicine ward. Intern. Emerg. Med., 4:241\u2013247.","journal-title":"Intern. Emerg. Med."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-10-200211190-00007"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/00365548.2011.572907","article-title":"Clinical implications of healthcare-associated infection in patients with community-onset acute pyelonephritis","volume":"43","author":"Ha Y.E.","year":"2011","unstructured":"Ha Y.E., , Kang C.I., , Joo E.J., , Park S.Y., , Kang S.J., , Wi Y.M., , Chung D.R., , Peck K.R., , Lee N.Y., , and Song J.H.. 2011. Clinical implications of healthcare-associated infection in patients with community-onset acute pyelonephritis. Scand. J. Infect. Dis., 43:587\u2013595.","journal-title":"Scand. J. Infect. Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.2.182"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1128\/AAC.41.8.1830","article-title":"Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens","volume":"41","author":"Jacoby G.","year":"1997","unstructured":"Jacoby G., , Han P., , and Tran J.. 1997. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens. Antimicrob. Agents. Chemother., 41:1830\u20131831.","journal-title":"Antimicrob. Agents. Chemother."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1128\/AAC.06212-11","article-title":"Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high","volume":"56","author":"Jeon J.H.","year":"2012","unstructured":"Jeon J.H., , Kim K., , Han W.D., , Song S.H., , Park K.U., , Rhee J.E., , Song K.H., , Park W.B., , Kim E.S., , Park S.W., et al. 2012. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high. Antimicrob. Agents. Chemother., 56:3043\u20133046.","journal-title":"Antimicrob. Agents. Chemother."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1086\/502310","article-title":"Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae","volume":"25","author":"Kang C.I.","year":"2004","unstructured":"Kang C.I., , Kim S.H., , Kim D.M., , Park W.B., , Lee K.D., , Kim H.B., , Oh M.D., , Kim E.C., , and Choe K.W.. 2004. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol., 25:860\u2013867.","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jinf.2012.01.008","article-title":"Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"64","author":"Kang C.I.","year":"2012","unstructured":"Kang C.I., , Park S.Y., , Chung D.R., , Peck K.R., , and Song J.H.. 2012. Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J. Infect., 64:533\u2013534.","journal-title":"J. Infect."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s15010-013-0441-z","article-title":"Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea","volume":"41","author":"Kim B.","year":"2013","unstructured":"Kim B., , Kim J., , Seo M.R., , Wie S.H., , Cho Y.K., , Lim S.K., , Lee J.S., , Kwon K.T., , Lee H., , Cheong H.J., et al. 2013. Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. Infection, 41:603\u2013612.","journal-title":"Infection"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00700-07"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1258\/ar.2011.110507"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1481-1491.2002"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/00365540701466140","article-title":"Clinical impact of infections caused by ESBL-producing E. coli and K. pneumoniae","volume":"39","author":"Kola A.","year":"2007","unstructured":"Kola A., , Maciejewski O., , Sohr D., , Ziesing S., , and Gastmeier P.. 2007. Clinical impact of infections caused by ESBL-producing E. coli and K. pneumoniae. Scand. J. Infect. Dis., 39:975\u2013982.","journal-title":"Scand. J. Infect. Dis."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/00365540151060806","article-title":"Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia","volume":"33","author":"Menashe G.","year":"2001","unstructured":"Menashe G., , Borer A., , Yagupsky P., , Peled N., , Gilad J., , Fraser D., , Riesenberg K., , and Schlaeffer F.. 2001. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand. J. Infect. Dis., 33:188\u2013193.","journal-title":"Scand. J. Infect. Dis."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-5-199309010-00001"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1128\/AAC.36.9.1991","article-title":"Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients","volume":"36","author":"Naumovski L.","year":"1992","unstructured":"Naumovski L., , Quinn J.P., , Miyashiro D., , Patel M., , Bush K., , Singer S.B., , Graves D., , Palzkill T., , and Arvin A.M.. 1992. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob. Agents. Chemother., 36:1991\u20131996.","journal-title":"Antimicrob. Agents. Chemother."},{"key":"e_1_3_2_22_2","first-page":"685","article-title":"Treatment of community-acquired uncomplicated urinary tract infection","volume":"81","author":"Pai H","year":"2011","unstructured":"Pai H. 2011. Treatment of community-acquired uncomplicated urinary tract infection. Korean J. Med., 81:685\u2013689.","journal-title":"Korean J. Med."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70041-0"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki166"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/archinte.168.17.1897","article-title":"Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli","volume":"168","author":"Rodriguez-Bano J.","year":"2008","unstructured":"Rodriguez-Bano J., , Alcala J.C., , Cisneros J.M., , Grill F., , Oliver A., , Horcajada J.P., , Tortola T., , Mirelis B., , Navarro G., , Cuenca M., et al. 2008. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch. Intern. Med., 168:1897\u20131902.","journal-title":"Arch. Intern. Med."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"beta-Lactam\/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodriguez-Bano J.","year":"2012","unstructured":"Rodriguez-Bano J., , Navarro M.D., , Retamar P., , Picon E., , and Pascual A.. 2012. beta-Lactam\/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin. Infect. Dis., 54:167\u2013174.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.5.671"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/649537","article-title":"Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis","volume":"50","author":"Rodriguez-Bano J.","year":"2010","unstructured":"Rodriguez-Bano J., , Picon E., , Gijon P., , Hernandez J.R., , Ruiz M., , Pena C., , Almela M., , Almirante B., , Grill F., , Colomina J., et al. 2010. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin. Infect. Dis., 50:40\u201348.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1257-1262.2006"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3947\/ic.2011.43.1.1","article-title":"Clinical Guideline for the Diagnosis and Treatment of Urinary Tract Infections: Asymptomatic Bacteriuria, Uncomplicated & Complicated Urinary Tract Infections, Bacterial Prostatitis","volume":"43","author":"The Korean Society of Infectious Diseases, The Korean Society for Chemotherapy, Korean Association of Urogenital Tract Infection and Inflammation, The Korean Society of Clinical Microbiology","year":"2011","unstructured":"The Korean Society of Infectious Diseases, The Korean Society for Chemotherapy, Korean Association of Urogenital Tract Infection and Inflammation, The Korean Society of Clinical Microbiology. 2011. Clinical Guideline for the Diagnosis and Treatment of Urinary Tract Infections: Asymptomatic Bacteriuria, Uncomplicated & Complicated Urinary Tract Infections, Bacterial Prostatitis. Infect. Chemother., 43:1\u201325.","journal-title":"Infect. Chemother."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.498-504.2006"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2013.0075","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2013.0075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2013.0075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:27:54Z","timestamp":1777667274000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2013.0075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1089\/mdr.2013.0075"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2013.0075","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}